ROS1 and non-small cell lung carcinoma: ,7 In an integrated analysis of three clinical trials (ALKA-372-001 [EudraCT, 2012–000148–88], STARTRK-1 [NCT2097810], and STARTRK-2 [NCT02568267]), entrectinib demonstrated clinically meaningful efficacy for locally advanced/metastatic NTRK fusion-positive solid tumours [63.5% objective response rate (ORR), N = 74] and ROS1 fusion-positive NSCLC (67.1% ORR, N = 161), with a manageable and favourable safety and tolerability profile.8